HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lebtahi, R. Articles by Le Guludec, D. Search for Related Content PubMed PubMed Citation Articles by Lebtahi, R. Articles by Le Guludec, D.

Somatostatin Receptor Scintigraphy and Gallium Scintigraphy in Patients with Sarcoidosis

Departments of Nuclear Medicine, Pneumology, and Rheumatology, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris; and Department of Internal Medicine, Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, Paris, France

Somatostatin receptor scintigraphy (SRS) has been shown to reveal sarcoidosis sites. The aim of this study was to prospectively compare SRS and gallium scintigraphy in the evaluation of pulmonary and extrapulmonary involvement in patients with proven sarcoidosis. Methods: Eighteen patients with biopsy-proven sarcoidosis were included. Nine were or recently had been receiving steroid therapy at the time of the examination. Planar gallium scintigraphy (head, chest, abdomen, and pelvis) and thoracic SPECT were performed at 48–72 h after injection of a mean dose of 138 ± 21 MBq ⁶⁷Ga. Planar SRS and thoracic SPECT were performed at 4 and 24 h after injection of a mean dose of 148 ± 17 MBq ¹¹¹In-pentetreotide. Results: Gallium scintigraphy found abnormalities in 16 of 18 patients (89%) and detected 64 of 99 clinically involved sites (65%). SRS found abnormalities in 18 of 18 patients and detected 82 of 99 clinically involved sites (83%). Of the 9 treated patients, gallium scintigraphy found abnormalities in 7 (78%), detecting 23 of 39 clinically involved sites (59%), whereas SRS found abnormalities in 9, detecting 32 of 39 clinically involved sites (82%). Conclusion: This study suggests that, compared with gallium scintigraphy, SRS appears to be accurate and contributes to a better evaluation of organ involvement in sarcoidosis patients, especially those treated with corticosteroids.

Key Words: somatostatin receptor scintigraphy • gallium scintigraphy • sarcoidosis

This article has been cited by other articles:

				Y. Nishiyama, Y. Yamamoto, K. Fukunaga, H. Takinami, Y. Iwado, K. Satoh, and M. Ohkawa Comparative Evaluation of 18F-FDG PET and 67Ga Scintigraphy in Patients with Sarcoidosis J. Nucl. Med., October 1, 2006; 47(10): 1571 - 1576. [Abstract] [Full Text] [PDF]

				R. Lebtahi, S. Moreau, S. Marchand-Adam, M.-P. Debray, M. Brauner, P. Soler, J. Marchal, O. Raguin, A. Gruaz-Guyon, J.-C. Reubi, et al. Increased Uptake of 111In-Octreotide in Idiopathic Pulmonary Fibrosis J. Nucl. Med., August 1, 2006; 47(8): 1281 - 1287. [Abstract] [Full Text] [PDF]

				A. F. Shorr, D. L. Helman, C. J. Lettieri, J. L. Montilla, and R. S. Bridwell Depreotide Scanning in Sarcoidosis: A Pilot Study Chest, October 1, 2004; 126(4): 1337 - 1343. [Abstract] [Full Text] [PDF]